Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001140361-16-062146
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-04-27 10:55:50
Reporting Period:
2016-04-26
Filing Date:
2016-04-27
Accepted Time:
2016-04-27 10:55:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1082038 Durect Corp DRRX Pharmaceutical Preparations (2834) 943297098
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1457518 First Eagle Value In Biotechnology Master Fund, Ltd. Citco Fund Services (Cayman Islands) Ltd
Regatta Office Park West Bay Road
Grand Cayman E9 KY1-1205
No No Yes No
1459688 21 April Fund, L.p. First Eagle Investment Management, Llc
1345 Avenue Of The Americas, 44Th Floor
New York NY 10105
No No Yes No
1459708 21 April Fund, Ltd. Citco Fund Services (Cayman Islands) Ltd
Regatta Office Park West Bay Road
Grand Cayman E9 KY1-1205
No No Yes No
1637141 First Eagle Holdings, Inc. 1345 Avenue Of The Americas
New York NY 10105
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-04-26 5,500,000 $1.25 19,881,546 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. Represents 1,064,843, 3,935,157 and 500,000 shares purchased by 21 April Fund, L.P. ("21 April LP"), 21 April Fund, Ltd. ("21 April Ltd."), and First Eagle Value in Biotechnology Master Fund, Ltd. ("FEVIBM" and, together with 21 April LP and 21 April Ltd., the "Funds"), respectively. First Eagle Investment Management, LLC ("FEIM") is (i) a general partner of 21 April LP, (ii) the registered investment adviser to the Funds, and (iii) a subsidiary of First Eagle Holdings, Inc. ("FEHI"). FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
  2. Represents 3,062,449, 11,232,153, and 5,586,944 shares held directly by 21 April LP, 21 April Ltd. and FEVIBM, respectively. FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.